Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Patrick Burnett Sells 943 Shares of Stock

Posted by Brian Himes on Nov 4th, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) EVP Patrick Burnett sold 943 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $31.86, for a total value of $30,043.98. Following the completion of the transaction, the executive vice president directly owned 116,649 shares of the company’s stock, valued at approximately $3,716,437.14. This trade represents a 0.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

On Wednesday, August 12th, Patrick Burnett sold 6,700 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $26.08, for a total transaction of $174,736.00.
On Tuesday, August 11th, Patrick Burnett sold 8,300 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $26.52, for a total transaction of $220,116.00.

Arcutis Biotherapeutics Price Performance

Arcutis Biotherapeutics stock traded up $2.05 during trading hours on Wednesday, reaching $34.05. 2,654,353 shares of the stock were exchanged, compared to its average volume of 1,836,721. The company has a market cap of $4.28 billion, a P/E ratio of 162.15 and a beta of 1.66. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 0.46. Arcutis Biotherapeutics, Inc. has a twelve month low of $19.30 and a twelve month high of $34.80. The stock has a 50 day moving average of $26.93 and a two-hundred day moving average of $25.33.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.12). The firm had revenue of $143.92 million during the quarter, compared to the consensus estimate of $142.59 million. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.05%. Equities analysts expect that Arcutis Biotherapeutics, Inc. will post 0.43 EPS for the current fiscal year.

Institutional Trading of Arcutis Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Montanova Capital LLC grew its position in shares of Arcutis Biotherapeutics by 0.9% in the 2nd quarter. Montanova Capital LLC now owns 12,437,000 shares of the company’s stock valued at $326,098,000 after buying an additional 110,000 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at about $276,502,000. Bank of America Corp DE bought a new position in shares of Arcutis Biotherapeutics during the second quarter worth about $78,330,000. Janus Henderson Group PLC raised its position in shares of Arcutis Biotherapeutics by 1.3% during the first quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company’s stock worth $43,684,000 after acquiring an additional 24,505 shares during the last quarter. Finally, Jupiter Topco LLC bought a new position in shares of Arcutis Biotherapeutics during the second quarter worth about $36,989,000.

Key Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

Positive Sentiment: Third-quarter revenue was $143.92 million, slightly above analysts’ $142.59 million estimate, providing a positive counterpoint to the earnings shortfall. MarketBeat earnings report
Neutral Sentiment: Several executives sold shares to cover tax withholding on vested equity awards. Most sales were relatively small; EVP Masaru Matsuda also sold 40,000 shares under a pre-arranged Rule 10b5-1 plan, reducing his reported holdings by 26.44%. The stated tax-related and planned nature of the transactions makes them less clearly bearish, though the larger sale may draw investor attention. SEC insider filing
Negative Sentiment: Adjusted quarterly earnings were $0.06 per share, below consensus estimates of approximately $0.17–$0.18 and unchanged from a year earlier. The miss could weigh on sentiment despite the revenue beat. Zacks earnings report

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $39.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, October 8th. Guggenheim upped their target price on Arcutis Biotherapeutics from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Weiss Ratings raised Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 29th. Needham & Company LLC lifted their price target on Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen cut Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 10th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Arcutis Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $39.12.

Read Our Latest Report on Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Profile

(Get Free Report)

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.